血清肿瘤标志物联合检测对肺癌诊断的价值  

Clinical Value of the Combined Detection of Serum Tumor Markers in Patients with Lung Cancer

作　　者：谢开红[1] 李国亮[1] 张忠山[1] 王小华[1] 周意华[1] 

机构地区：[1]湘南学院附属医院肿瘤科,湖南郴州423000

出　　处：《湘南学院学报（医学版）》2007年第3期16-18,共3页Journal of Xiangnan University（Medical Sciences）

摘　　要：目的探讨血清肿瘤标记物CEA、Cyfra21-1、NSE联合检测对肺癌的诊断、病理分型和分期的临床应用价值。方法采用放射免疫技术,检测96例肺癌患者化学治疗前,30例健康人血清CEA、Cyfra21-1、NSE水平。结果肺癌组治疗前CEA、Cyfra21-1、NSE水平高于正常对照组(P均<0.05);3种肿瘤标记物在肺腺癌、鳞癌和小细胞肺癌中的水平有差异(P均<0.05);肿瘤标记物水平随临床分期增加呈升高趋势,肿瘤标志物的敏感性也增加;3种肿瘤标记物联合检测与各单项指标检测比较,对肺癌诊断的敏感性增高(P<0.05)。结论血清CEA、Cyfra 21-1、NSE联合检测用于肺癌的诊断有较好的临床参考价值,并有助于肺癌病理类型和临床分期的评估。Objective To investigate the value of combined detection of serum CEA, Cyfra 21 - 1 and NSE in the diagnosis, Pathological classification and stage in patients with lung carcinoma. Methods Using immunoradiometric assey, the Serum CEA, Cyfra 21 - 1 and NSE levels were measured in 96 cases of primary lung cancer before chemotherapy, as well as 30 cases of healthy controls. Results The levels of CEA, Cyfra 21 - 1 and NSE in patients with primary lung carcinoma before chemotherapy were significantly higher than those in normal controls （ P 〈0.05）. Signle analysis showed that high positive rates of CEA, Cyfra 21 - 1 and NSE were seen in adeno- carcinoma, squamous carcinoma and small cell lung cancer respectively（ P 〈 0.05）. As clinical stage increased, the levels and sensitivity of CEA, Cyfra 21 - 1 and NSE in patients were more higher（ P 〈 0.05） ;Combined de- tection of the setum or markers had an increased sensitivity（ P 〈 0.05）. Conclusion Combined detection of serum CEA, Cyfra 21 - 1 and NSE has a higher sensitivity in the diagnosis of lung cancer.

关 键 词：肺肿瘤 癌胚抗原 细胞角蛋白 神经元特异性烯醇化酶 肿瘤标记物 

分 类 号：R734.2[医药卫生—肿瘤]